Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
about
Getting the balance right: Established and emerging therapies for major depressive disordersDuloxetine in the treatment of stress urinary incontinencePharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoringWhat is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.Duloxetine in the treatment of generalized anxiety disorder.Continuation treatment of major depressive disorder: is there a case for duloxetine?Halothane-anesthetized rabbit: a new experimental model to test the effects of besipirdine and duloxetine on lower urinary tract function.New and emerging therapeutic agents for the treatment of fibromyalgia: an update.Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathyQuantitative determination of duloxetine and its metabolite in rat plasma by HPLC-MS/MS.Duloxetine for the treatment of fibromyalgia.Duloxetine in the treatment of major psychiatric and neuropathic disorders.Serotonin and noradrenaline reuptake inhibitors improve micturition control in miceRapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathyEffect of age on the pharmacokinetics of duloxetine in women.Duloxetine: a dual reuptake inhibitor.Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects.Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.Safety and adverse event profile of duloxetine.Duloxetine in diabetic neuropathy.Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groupsDuloxetine: a new selective and dual-acting antidepressant.Review of duloxetine in the management of diabetic peripheral neuropathic pain.The impact of CYP allelic variation on antidepressant metabolism: a review.Pharmacokinetics and Safety of Duloxetine Enteric-coated Tablets in Chinese Healthy Volunteers: A Randomized, Open-label, Single- and Multiple-dose Study.Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes.Duloxetine in the treatment of major depressive disorder.Duloxetine for the treatment of generalized anxiety disorder: a review.Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.A review of SSRIs and SNRIs in neuropathic pain.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Overview of metabolite safety testing from an industry perspective.Duloxetine: clinical pharmacokinetics and drug interactions.Clinically significant drug interactions with newer antidepressants.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.Duloxetine: a review of its use in the management of major depressive disorder in older adults.Pharmacokinetic considerations for therapies used to treat interstitial cystitis.Clinical applications of CYP genotyping in psychiatry.
P2860
Q24610225-3C8FEE3B-6111-4A7C-8E7C-F86E45527A56Q24680252-162B975C-EB6E-40F2-B4A2-929AD3136E9CQ27027293-67219062-F5D4-436C-80E5-38D628DEE695Q33278984-94455FCB-22D5-4888-8057-0C1D7E7977ABQ33716001-39A7427D-7A40-4B66-B916-05FFFDBDA8C3Q33735030-0E67EA88-05B4-49FA-9681-59CCD9096798Q33755767-8708AF99-018E-4547-B5A1-0BDE74D5BEFAQ34149404-FAAB7D5C-6C7D-48D6-86BE-EF92363819DBQ34418303-F07BC75E-E7F3-4487-B90E-0B3F78B83222Q34623747-DC2FF7D1-7501-4B5C-B6C0-F45A80610AE0Q34631485-736D4F2F-0EA3-4BE9-AFA1-281227991B81Q34663934-B7F558EF-CE0D-4C57-A363-B0DF843F38F6Q34770302-9D5AF814-A9AB-4EBE-82DB-A55AB91365FCQ35220015-A8F30E78-0FB1-487F-A009-0D7AB33383A1Q35571849-784C6199-707A-4714-8D09-C210BDD52227Q35825909-52626899-E4F6-4206-B3CC-4B5463E92A89Q35937708-6DC63319-1C52-4C75-AB4B-47570E3A50AAQ36024984-E4635DE5-5318-4EFA-A717-0B0D06A2A50AQ36150758-C6287DED-CAE9-4BC4-8002-A2549EB1E10FQ36299961-3D6D4400-F3AD-4FF2-8079-2C364D5132C5Q36376417-9CD66264-2698-49D7-AA6A-F95CE25AFEF9Q36395440-1F329C52-143B-43FD-A9DE-CA1808FA1A74Q36407366-A54AA702-B61D-475E-8AFE-32F4983EC92DQ36596907-041362D9-AD55-4779-AD51-ACD69048B666Q36725210-8AA1C195-E1AD-4F1E-B46D-F29FA4AC437CQ36832344-5DFF803E-5960-49A8-9F90-57D583F8805CQ37097643-EF7DAD16-4D5E-4968-89DB-084F0DFD8079Q37125752-5062E88E-2445-4E47-BFEA-52B718CD7B70Q37224580-E14C369D-C3A2-47BB-A758-99216BB05CE5Q37733559-F0EFCC6B-4CCD-4A30-9B95-EEB2A935E9D3Q37773988-300C481B-C6D7-46AF-AC91-8E10890C4786Q37808483-A046DBB5-6D0E-41B8-934D-04188FAD06DDQ37810227-392BE512-D133-4C81-A80A-77165D448D9EQ37848815-5924F4D7-2BBE-492B-9029-24A62E3194D2Q37968621-647D941B-2E8F-4D75-8019-92D48E537F56Q38008438-3D4EE383-009D-485E-AB8D-4D38FEC29EB7Q38020236-B434566A-D63E-42E4-97EE-1B7A9AA281CDQ38067355-CE7E3154-FF12-4DEF-8892-140A501BA4B9Q38195318-FA3BCD0B-AD89-4792-A1A3-349D689A5B2DQ38247063-72728B6C-FDF2-47A4-A1BF-578B48FF126C
P2860
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@en
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@nl
type
label
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@en
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@nl
prefLabel
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@en
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@nl
P2093
P356
P1476
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
@en
P2093
Gillespie TA
Knadler MP
P304
P356
10.1124/DMD.31.9.1142
P577
2003-09-01T00:00:00Z